Ashling Wahner

Key experts across oncology specialties share how they prioritize patient safety in their practices related to AE awareness and mitigation strategies.

Response to evorpacept plus zanidatamab was predicted by high levels of CD47 expression in patients with HER2-positive metastatic breast cancer.

Ana C. Garrido-Castro, MD, discusses the implications of 3 of the biggest phase 3 TNBC trials from 2025 and how they may reshape frontline management.

Find out which of this year’s Miami Breast presentations are anticipated to be “heard on Friday and used on Monday.”

Treatment with subcutaneous amivantamab plus pembrolizumab was deemed effective and safe in patients with recurrent or metastatic, PD-L1–positive HNSCC.

Igor Makhlin, MD, notes the imaging modalities used in metastatic breast cancer and highlights FES-PET/CT as a specific modality for ER-positive disease.

Read a refresh of the top FDA news in breast cancer from February 2026, including upcoming decision dates, a fast-tracked drug, and REMS safety updates.

In case you missed any, read a recap of the episodes of OncLive On Air that aired in February 2026.

The bispecific ADC iza-bren elicited PFS and OS benefits compared with chemotherapy in pretreated, unresectable, locally advanced or metastatic TNBC.

Sophia O’Brien, MD, discusses the role of nuclear medicine in lobular breast cancer diagnosis and staging, as well as use criteria for FES-PET/CT.

Will the FDA approve giredestrant plus everolimus for ESR1-mutated, ER-positive, HER2-negative advanced breast cancer after prior endocrine therapy?

Subcutaneous amivantamab monotherapy received breakthrough therapy designation from the FDA for recurrent or metastatic, HPV-unrelated HNSCC.

Martha Welman, MD, discusses the value of personalized patient relationships over technology, especially for populations with limited access to resources.

The FDA has approved acalabrutinib plus venetoclax for the treatment of adult patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

David Rimm, MD, PhD, discusses ways that the use of ADCs in breast cancer might adapt to reflect emerging categories of detectable HER2 expression levels.

Jason Aboudi Mouabbi, MD, discusses challenges associated with diagnosing lobular breast cancer and the promising predictive value of FES-PET/CT imaging.

The FDA approved a monthly dosing schedule of amivantamab and hyaluronidase for the first-line treatment of patients with EGFR-mutated, advanced NSCLC.

David Rimm, MD, PhD, discusses whether ADCs should be considered similar to targeted therapy, or whether this class of agents is more akin to chemotherapy.

The FDA has issued REMS safety updates regarding the use of the denosumab biosimilars Enoby and Ospomyv for patients with breast and prostate cancers.

OncLive heard from experts across oncology specialties about the biggest updates from the 2026 Transplantation and Cellular Therapy Meetings.

Adoptive cell therapy elicited MRD-negative responses with low rates of GVHD and neurotoxicities in adult patients with high-risk B-ALL.

Orca-T/reduced-intensity conditioning was effective and decreased GVHD incidence vs PTCy/reduced-intensity conditioning in hematologic malignancies.

Prophylactic dexamethasone did not reduce the risk of developing DNT, nor the severity of DNT presentation, in cilta cel–treated myeloma with high ALC.

Acalabrutinib yielded durable organ-specific responses and a manageable safety profile in patients with steroid-refractory chronic graft-vs-host disease.

The FDA granted priority review to Dato-DXd for patients with first-line unresectable or metastatic TNBC who are not eligible to receive immunotherapy.

Fangfang Yan, PhD, discusses findings from a multi-omic analysis that identified mechanisms of pirtobrutinib resistance in mantle cell lymphoma.

The FDA has accepted a BLA seeking the approval of ivonescimab plus chemotherapy for EGFR-mutated, advanced, nonsquamous NSCLC after TKI progression.

The gremlin-1–directed monoclonal antibody ginisortamab showed early efficacy signals when combined with SOC therapy in patients with advanced GI tumors.

The FDA has approved daratumumab and hyaluronidase plus VRd for adult patients with newly diagnosed multiple myeloma who are not eligible for ASCT.

Treatment with first-line metronomic cyclophosphamide did not significantly improve TTF, PFS, or OS vs doxorubicin in advanced soft tissue sarcoma.